Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARMA-01
2024-511844-18-00Phase 2Authorised
- Sponsor
- Uppsala University
- Start
- May 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ELC-301 in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and 1 more, sponsored by Uppsala University. Planned start May 2024; status: authorised.
02
Drugs
ELC-301
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)lymphoma
Beyond the preview
Go deeper on 2024-511844-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511844-18-00.